healthcare-thumbnail.png

Non-Hodgkin Lymphoma Market Research Report

Published: 2025 - January

Report Code: VMR-17539

Region: Global

Request Sample
Customization
Ask an Expert
Enquire Enquire Before Buying

Non-Hodgkin Lymphoma Market Analysis 

The Non-Hodgkin Lymphoma (NHL) Market is a dynamic and evolving segment of the oncology industry, focused on addressing the unmet needs of patients with diverse subtypes of B-cell, T-cell, and NK-cell malignancies. Non-Hodgkin lymphoma, characterized by the abnormal growth of lymphocytes in the immune system, encompasses multiple subtypes with varying treatment complexities, prognosis, and therapeutic approaches. This market encompasses diagnostic innovations, targeted therapies, immunotherapies, and advanced drug delivery systems.

Disruptive Impact and Opportunities:

The NHL market is undergoing a transformation driven by the emergence of innovative treatments that improve survival rates, enhance patient convenience, and reduce side effects. This disruption opens up opportunities for novel drugs such as Tisagenlecleucel, AB-205, Epcoritamab, AUTO4, ZN-d5, and HRS-3738, which focus on addressing challenges associated with relapse, resistance, and suboptimal responses. Breakthrough therapies like CAR-T cell treatments, bispecific antibodies, and next-generation BTK inhibitors are rapidly gaining traction for their efficacy in hard-to-treat cases.

Non-Hodgkin Lymphoma Market Segmentation - Emerging Drugs

  • Tisagenlecleucel

  • AB-205

  • Epcoritamab

  • AUTO4, ZN-d5

  • HRS-3738

Non-Hodgkin Lymphoma Market Segmentation - Marketed Drugs

  • Ibrutinib (Imbruvica)

  • Acalabrutinib (Calquence)

  • Zanubrutinib (Brukinsa)

  • Pirtobrutinib (Jaypirca)

  • Copanlisib (Aliquopa)

Key Companies:

  • AbbVie, Genmab

  • Novartis

  • Angiocrine Bioscience

  • Autolus, Zentera Therapeutics

  • Jiangsu Hengrui Medicine

Non-Hodgkin Lymphoma Market Segmentation -  By Type

·  B-Cell Lymphoma

  • Diffuse Large B-Cell Lymphoma (DLBCL)

  • Follicular Lymphoma

  • Mantle Cell Lymphoma

  • Marginal Zone B-Cell Lymphoma

  • Burkitt Lymphoma

  • Small Lymphocytic Lymphoma (SLL)

  • Primary Mediastinal Large B-Cell Lymphoma

  • Others

·  T-Cell Lymphoma

  • Peripheral T-Cell Lymphoma

  • Cutaneous T-Cell Lymphoma (CTCL)

  • Adult T-Cell Leukemia/Lymphoma

  • Angioimmunoblastic T-Cell Lymphoma

  • Anaplastic Large Cell Lymphoma

  • Enteropathy-Associated T-Cell Lymphoma

  • Others

·  NK-Cell Lymphoma

·  Others

  • Indolent Lymphomas

  • Aggressive Lymphomas

Non-Hodgkin Lymphoma Market Segmentation -  By Administration Type

·  Oral Administration

  • Capsules

  • Tablets

·  Injectable Administration

  • Intravenous (IV)

  • Subcutaneous (SC)

  • Intramuscular (IM)

·  Others

  • Intrathecal

  • Topical

What’s in It for You?

  • Gain insights into the competitive landscape and emerging opportunities in NHL therapy.

  • Explore market growth drivers such as advancements in immunotherapy and precision medicine.

  • Identify strategic entry points and areas for innovation within niche NHL subtypes.

  • Leverage the report’s analysis for strategic planning, product pipeline development, and investment decision-making.

1. Non-Hodgkin Lymphoma Market - Executive Summary                                             

               1.1. Introduction                             

               1.2. Objectives                 

               1.3. Key Findings                             

                              1.3.1. Market Size 2022 & 2032: By Key Country (10MM)

                              1.3.2. Global Market Size 2022 & 2032: By Key Segment  

                              1.3.3. Key Investments & Startup Analysis             

               1.4. Research Methodology                        

                                            

2. Understanding the Disease                                   

               2.1. Disease Overview                   

               2.2. Classification                            

               2.3. Signs and Symptoms                             

               2.4. Risk Factors              

               2.5. Causes                       

               2.6. Disease Biology & Digital Innovations                            

               2.7. Stages & Staging System                     

               2.8. Diagnostic Algorithm                            

               2.9. Current Treatment Practices & Algorithm                     

               2.10. Current Standard of Care and Treatment Gaps                        

               2.11. Patient Demographics and Treatment Pathways                     

                                            

3. Guidelines                                    

                                            

4. Unmet Needs                                            

                                            

5. Epidemiology and Patient Population                                

               5.1. Epidemiology Key Findings                  

               5.2. Assumptions and Rationale: 10MM                

               5.3. Epidemiology Scenario: 10MM                         

               5.4. U.S. Epidemiology Scenario                

               5.5. EU-5 Epidemiology                 

                              5.5.1. U.K. Epidemiology Scenario            

                              5.5.2. Germany Epidemiology Scenario   

                              5.5.3. France Epidemiology Scenario       

                              5.5.4. Italy Epidemiology Scenario            

                              5.5.5. Spain Epidemiology Scenario          

               5.6. Japan Epidemiology Scenario                            

               5.7. China Epidemiology Scenario                            

               5.8. Australia Epidemiology Scenario                      

               5.9. India Epidemiology Scenario                             

                                            

6. Real-world Data & Real-world Evidence                                           

                                            

7. Drug Development Landscape                                            

               7.1. Existing Key Drug Candidate Profiles/ Marketed Therapies                    

                              7.1.1. Ibrutinib (Imbruvica)          

                                             7.1.1.1. Product Description

                                             7.1.1.2. Regulatory Milestones

                                             7.1.1.3. Other Developmental Activities

                                             7.1.1.4. Pivotal Clinical Trials

                                             7.1.1.5. Ongoing Current Pipeline Activity

                              7.1.2. Acalabrutinib (Calquence)

                                             7.1.2.1. Product Description

                                             7.1.2.2. Regulatory Milestones

                                             7.1.2.3. Other Developmental Activities

                                             7.1.2.4. Pivotal Clinical Trials

                                             7.1.2.5. Ongoing Current Pipeline Activity

                              7.1.3. Zanubrutinib (Brukinsa)     

                                             7.1.3.1. Product Description

                                             7.1.3.2. Regulatory Milestones

                                             7.1.3.3. Other Developmental Activities

                                             7.1.3.4. Pivotal Clinical Trials

                                             7.1.3.5. Ongoing Current Pipeline Activity

                              7.1.4. Pirtobrutinib (Jaypirca)      

                                             7.1.4.1. Product Description

                                             7.1.4.2. Regulatory Milestones

                                             7.1.4.3. Other Developmental Activities

                                             7.1.4.4. Pivotal Clinical Trials

                                             7.1.4.5. Ongoing Current Pipeline Activity

                              7.1.5. Copanlisib (Aliquopa)         

                                             7.1.5.1. Product Description

                                             7.1.5.2. Regulatory Milestones

                                             7.1.5.3. Other Developmental Activities

                                             7.1.5.4. Pivotal Clinical Trials

                                             7.1.5.5. Ongoing Current Pipeline Activity

               7.2. Competitive Analysis and Differentiation                      

               7.3. Overview of Similar/Competing Drugs in Clinical Trials                           

               7.4. Future Trends and Emerging Drugs                 

                              7.4.1. Tisagenlecleucel   

                                             7.4.1.1. Product Description

                                             7.4.1.2. Clinical Development

                                             7.4.1.3. Safety and Efficacy

                              7.4.2. AB-205    

                                             7.4.2.1. Product Description

                                             7.4.2.2. Clinical Development

                                             7.4.2.3. Safety and Efficacy

                              7.4.3. Epcoritamab          

                                             7.4.3.1. Product Description

                                             7.4.3.2. Clinical Development

                                             7.4.3.3. Safety and Efficacy

                              7.4.4. AUTO4     

                                             7.4.4.1. Product Description

                                             7.4.4.2. Clinical Development

                                             7.4.4.3. Safety and Efficacy

                                            

8. Regulatory Strategy and Potential Challenges                                

               8.1. Regulatory Pathways in Key Markets                             

               8.2. Anticipated Regulatory Hurdles and Mitigation Strategies                     

               8.3. Case Studies in Oncology Drug Regulation                    

               8.4. Impact of Potential Changes to Regulatory Framework                          

                                            

9. Commercial Landscape                                          

               9.1. Market Size & Growth Rates                             

               9.2. Key Approvals & Anticipated Loss of Exclusivity                         

               9.3. PESTLE & Porter’s Five Forces Analysis                          

               9.4. Market Shares, Positioning/Ranking                

               9.5. Market Drivers                        

               9.6. Identification of Threats                      

               9.7. Digital Evolution in Commercialization                           

                                            

10. Market Segmentation                                           

               10.1. Market by Type                    

                              10.1.1. B-cell lymphomas            

                              10.1.2. T-cell lymphoma 

               10.2. Market by Treatment                         

                              10.2.1. Surgery  

                              10.2.2. Chemotherapy   

                              10.2.3. Immunotherapy 

                              10.2.4. Radiation Therapy            

                              10.2.5. Others   

                                            

11. Pricing, Reimbursement, and Access                              

               11.1. Competitive Pricing Analysis                           

               11.2. Reimbursement Landscape and Challenges               

               11.3. Strategies for Market Access and Equity                     

               11.4. Patient Spending/Expenditure Analysis                      

                                            

12. Future Trends, Disruptions, and Opportunities                                           

               12.1. Analysis of Emerging Trends                           

               12.2. Technological Impact                         

               12.3. Impact of Potential Market Disruptors                        

               12.4. Opportunities for Future Development and Expansion                         

               12.5. Considerations for Investment Opportunities                           

                                            

13. Global Market Dynamics                                     

               13.1. Regional Regulatory Disparities                      

               13.2. Cross-Border Partnership Strategies                            

               13.3. Global Supply Chain Dynamics                       

               13.4. Case Studies: Success and Failure in Global Markets                             

               13.5. Strategies for Global Expansion and Localization                     

                                            

14. Company Profiles                                   

               14.1. Astellas Pharma US, Inc                    

               14.2. AstraZeneca PLC                  

               14.3. Bayer AG                 

               14.4. Bristol Myers Squibb Company                      

               14.5. Eli Lilly and Company                         

               14.6. GSK plc                    

               14.7. F. Hoffmann La-Roche Ltd.               

               14.8. Seagen Inc                             

               14.9. Takeda Pharmaceutical Company Ltd.                         

               14.10. Teva Pharmaceutical Industries Ltd.                          

Download Sample

↻

The field with (*) is required.

Choose License Type

$

2500

$

4250

$

5250

$

6900

Request Sample
Customization
Ask an Expert
Enquire Before Buying
customer-support

Analyst Support

Every order comes with Analyst Support.

report-custom

Customization

We offer customization to cater your needs to fullest.

verify

Verified Analysis

We value integrity, quality and authenticity the most.

© 2025 Virtue Market Research. All Rights Reserved.